Search

Your search keyword '"Tarl W Prow"' showing total 6 results
Start Over Author "Tarl W Prow" Publisher elsevier
6 results on '"Tarl W Prow"'

3. The Potential for Metal Nanoparticle-Enhanced Radiotherapy in Dermatology

Author

V.L.T. Hoang, Matthew Foote, Tarl W. Prow, Hoang, VLT, Foote, MC, and Prow, TW

Subjects
skin, Chemotherapy, Materials science, integumentary system, medicine.medical_treatment, particle delivery, Human skin, medicine.disease, elongated microparticle, Radiation therapy, medicine.anatomical_structure, In vivo, Colloidal gold, gold nanoparticles, medicine, Cancer research, Stratum corneum, Skin cancer, radiotherapy, Stratum basale, Biomedical engineering
Abstract

Together with chemotherapy and surgery, radiotherapy is a major technique in the management of cancer treatment. Current topical and surgical therapies work from the surface of the skin down; this means that the majority of the effective dose is at the surface of the skin, but the source of the disease is usually at the deepest part of the viable epidermis, the stratum basale. The ultimate goal of radiotherapy is to destroy all the diseased cells with minimal effect to surrounding tissues. In this chapter, we summarize the current status of in vitro and in vivo research and development, toward the use of metal nanoparticles in enhancing radiotherapy. We also explore the potential for effectively and selectively treating neoplastic skin disease using a nanodermatology approach. Metal nanoparticles are now recognized as a possible alternative to small drug molecules in skin cancer treatment. We present our unpublished data on penetration of gold nanoparticles (GNP) into human skin that support the hypothesis that elongated silica microparticles are able to assist GNPs penetration through the stratum corneum and hence into viable human skin.

Published
2016
Full Text
View/download PDF

4. Contributors

Author

Mona M.A. Abdel-Mottaleb, Allesandro Afornali, Marcel Ameloot, Firoz Anwar, F.A. Al-Abbasi, Anthony A. Attama, Giuseppina Barrera, Sarwar Beg, Heather A.E. Benson, Aaron J. Brady, Jiezhong Chen, Lucy L. Chen, Eric Stefano Ciamporcero, Martina Daga, Sarah Deville, Chiara Dianzani, Ryan F. Donnelly, Labiba El-Khourdagui, Nesma El-Sayed, Socorro Espuelas, Anitha Ethirajan, Conor L. Evans, Carlo Ferretti, Matthew C. Foote, Adam Friedman, Casimiro Luca Gigliotti, Yolanda Gilaberte, Ee Teng Goh, Jeffrey E. Grice, Aswathi R. Hegde, Van L.T. Hoang, G. Louis Hornyak, Sasan Jalili-Firoozinezhad, Ángeles Juarranz, Georgia Kirby, Vikas Kumar, Angelo Landriscina, Jun Li, Zongxi Li, Xing-Jie Liang, Lynlee L. Lin, Márcio Lorencini, Morteza Mahmoudi, Giovanni Maina, Jyothsna Manikkath, Srujan Kumar Marepally, Omid Mashinchian, Yousuf Mohammed, Breanne Mordorski, Esther Moreno, Srinivas Mutalik, Mohammad Norouzi, Joshua D. Nosanchuk, Ebele B. Onuigbo, Megan J. Osmond-McLeod, Harendra S. Parekh, Ievgenia Pastushenko, Rozhin Penjweini, Stefania Pizzimenti, Lucia Prieto-Torres, Tarl W. Prow, Mahfoozur Rahman, Jayakumar Rajadas, Fiorenza Rancan, Anil K. Rao, Joy N. Reginald-Opara, Michael S. Roberts, Jamie Rosen, Federica Rossi, Ricardas Rotomskis, Marc Schneider, Juana Schwartz, Masoud Soleimani, Aaron Tan, Juan Tao, Shima Tavakol, Emmanuel M. Uronnachi, Praveen Kumar Vemula, Min Wang, Steven Q. Wang, Chenjie Xu, Miko Yamada, Gian Paolo Zara, Xu Dong Zhang, and Yi Zhang

Published
2016
Full Text
View/download PDF

5. List of Contributors

Author

Daniel Axelrod, Melanie Bokstad, Martin J. Booth, Julian Borejdo, Alessandra Cambi, Julien Colombelli, Ali Ertürk, Eugenio F. Fornasiero, Sung-Sik Han, Samie R. Jaffrey, Min-Kyo Jung, Sandra de Keijzer, Jun-Sung Kim, Lynlee L. Lin, Er Liu, Corinne Lorenzo, Ohad Medalia, Marjolein B.M. Meddens, John P. Nolan, Felipe Opazo, Chan-Gi Pack, Brian R. Patton, Daniel A. Peterson, Jeremy Pike, Tarl W. Prow, Joshua Z. Rappoport, E. Hesper Rego, Yasushi Sako, Lin Shao, Alex Small, Mi-Roung Song, Shane Stahlheber, Rita L. Strack, Jennifer A. Thorley, and Miko Yamada

Published
2014
Full Text
View/download PDF

6. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients

Author

Miko Yamada, Dennis M. Miller, Melinda Lowe, Casey Rowe, Dominic Wood, H. Peter Soyer, Kelly Byrnes-Blake, Julia Parrish-Novak, Laura Ishak, James M. Olson, Gordon Brandt, Paul Griffin, Lynda Spelman, and Tarl W. Prow

Subjects
Skin neoplasms, Fluorescent dyes, Cystine-knot miniproteins, Medicine (General), R5-920
Abstract

BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent that selectively detects malignant tissue and can be used in real time to guide tumor resection. The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of BLZ-100 and to explore the pharmacodynamics of fluorescence imaging of skin tumors. In this first-in-human study, BLZ-100 was administered intravenously to 21 adult patients 2 days before excising known or suspected skin cancers. Doses were 1, 3, 6, 12, and 18 mg, with 3–6 patients/cohort. Fluorescence imaging was conducted before and up to 48 h after dosing. BLZ-100 was well tolerated. There were no serious adverse events, deaths, or discontinuations due to adverse events, and no maximum tolerated dose (MTD) was identified. Headache (n = 2) and nausea (n = 2) were the only BLZ-100 treatment-related adverse events reported for >1 patient. Median time to maximal serum concentration was

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results